TOB-2 Tobacco use Treatment provided or Offered and the subset measure TOB-2a: Tobacco Use Treatment

The measure is reported as an overall rate which includes all hospitalized patients 18 years of age and older to whom tobacco use treatment was provided during the hospital stay, or offered and refused, and a second rate, a subset of the first, which includes only those patients who received tobacco use treatment during the hospital stay.

Date Reviewed: July 21, 2018

Measure Info

NQF 1654 CMS TOB-2a NQF Endorsement Removed
Measure Type
Measure Steward
The Joint Commission
Clinical Topic Area
Prevention and Wellness
Substance Use

Care Setting
Data Source
Electronic Health Records
Paper Medical Records

ACP does not support NQF measure #1654: “TOB-2 Tobacco use Treatment Provided or Offered and the subset measure TOB-2a: Tobacco Use Treatment.” This measure represents an important clinical concept; however, the specifications are flawed, developers do not cite highquality evidence to form the basis of the measure and facilities and individual clinicians could face challenges with implementation. Developers should consider revising the specifications to align with the clinical recommendations of the United States Preventive Services Task Force (USPSTF). The Task Force recommends that clinicians screen for tobacco use, and prescribe behavioral interventions AND U.S. FDA-approved pharmacotherapy for adults who use tobacco. The benefits of counseling without pharmacotherapy are unclear. Furthermore, specifications should include exclusion criteria for patients who expire during hospitalization and patients who have contraindications to pharmacotherapy. Additionally, measure specifications should clearly define what constitutes “cognitively impaired” in the exclusion criteria and “practical counseling” in the numerator specifications. Moreover, the denominator specifications should clearly define what constitutes “inpatient” status. For example, implementation may penalize clinicians treating patients who are classified as observational- or ambulatory-admission status. Otherwise, implementation could pressure clinicians to spend a disproportionate amount of time on tobacco use treatment, when other conditions should take precedence.